Jill A. Meyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jill A. Meyer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Amanda A. Bedwell
Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publicationAndrew R. Marks
Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA
1 shared publication- Haikel Dridi
Columbia University
1 shared publication Jonathan S. Peters
Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication- Kaylee Wedderburn-Pugh
Department of Physiology and Cellular Biophysics, Clyde and Helen Wu Center for Molecular Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA
1 shared publication - Khalid Said Mohammad
Department of Anatomy, College of Medicine, Alfaisal University
1 shared publication
Latest Publications
- 27 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (715) , eadf8977
Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice
Chemotherapy-induced cognitive dysfunction (chemobrain) is an important adverse sequela of chemotherapy. Chemobrain has been identified by the National Cancer Institute as a poorly understood problem for which current management or treatment strategies are limited or ineffective. Here, we show that chemotherapy treatment with doxorubicin (DOX) in a breast cancer mouse model induced protein kinase A (PKA) phosphorylation of the neuronal ryanodine receptor/calcium (Ca2+) channel type 2 (RyR2), RyR2 oxidation, RyR2 nitrosylation, RyR2 calstabin2 depletion, and subsequent RyR2 Ca2+leakiness. Chemotherapy was furthermore associated with abnormalities in brain glucose metabolism and neurocognitive dysfunction in breast cancer mice. RyR2 leakiness and cognitive dysfunction could be ameliorated by treatment with a small molecule Rycal drug (S107). Chemobrain was also found in noncancer mice treated with DOX or methotrexate and 5-fluorouracil and could be prevented by treatment with S107. Genetic ablation of the RyR2 PKA phosphorylation site (RyR2-S2808A) also prevented the development of chemobrain. Chemotherapy increased brain concentrations of the tumor necrosis factor–α and transforming growth factor–β signaling, suggesting that increased inflammatory signaling might contribute to oxidation-driven biochemical remodeling of RyR2. Proteomics and Gene Ontology analysis indicated that the signaling downstream of chemotherapy-induced leaky RyR2 was linked to the dysregulation of synaptic structure–associated proteins that are involved in neurotransmission. Together, our study points to neuronal Ca2+dyshomeostasis via leaky RyR2 channels as a potential mechanism contributing to chemobrain, warranting further translational studies.
- 27 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (715) , eadf8977
Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice
Chemotherapy-induced cognitive dysfunction (chemobrain) is an important adverse sequela of chemotherapy. Chemobrain has been identified by the National Cancer Institute as a poorly understood problem for which current management or treatment strategies are limited or ineffective. Here, we show that chemotherapy treatment with doxorubicin (DOX) in a breast cancer mouse model induced protein kinase A (PKA) phosphorylation of the neuronal ryanodine receptor/calcium (Ca2+) channel type 2 (RyR2), RyR2 oxidation, RyR2 nitrosylation, RyR2 calstabin2 depletion, and subsequent RyR2 Ca2+leakiness. Chemotherapy was furthermore associated with abnormalities in brain glucose metabolism and neurocognitive dysfunction in breast cancer mice. RyR2 leakiness and cognitive dysfunction could be ameliorated by treatment with a small molecule Rycal drug (S107). Chemobrain was also found in noncancer mice treated with DOX or methotrexate and 5-fluorouracil and could be prevented by treatment with S107. Genetic ablation of the RyR2 PKA phosphorylation site (RyR2-S2808A) also prevented the development of chemobrain. Chemotherapy increased brain concentrations of the tumor necrosis factor–α and transforming growth factor–β signaling, suggesting that increased inflammatory signaling might contribute to oxidation-driven biochemical remodeling of RyR2. Proteomics and Gene Ontology analysis indicated that the signaling downstream of chemotherapy-induced leaky RyR2 was linked to the dysregulation of synaptic structure–associated proteins that are involved in neurotransmission. Together, our study points to neuronal Ca2+dyshomeostasis via leaky RyR2 channels as a potential mechanism contributing to chemobrain, warranting further translational studies.